Share on StockTwits

United Therapeutics (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 9,640 shares of the company’s stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $93.13, for a total value of $897,773.20. Following the completion of the transaction, the chief executive officer now directly owns 140 shares in the company, valued at approximately $13,038. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of United Therapeutics from a “neutral” rating to an “outperform” rating in a research note on Thursday. They now have a $112.00 price target on the stock. Separately, analysts at Wedbush raised their price target on shares of United Therapeutics from $119.00 to $133.00 in a research note on Thursday, July 31st. Finally, analysts at RBC Capital raised their price target on shares of United Therapeutics from $90.00 to $93.00 in a research note on Thursday, July 31st. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $102.87.

United Therapeutics (NASDAQ:UTHR) traded up 0.41% on Friday, hitting $94.13. 362,885 shares of the company’s stock traded hands. United Therapeutics has a 52 week low of $70.34 and a 52 week high of $116.65. The stock’s 50-day moving average is $91.46 and its 200-day moving average is $95.51. The company has a market cap of $4.449 billion and a P/E ratio of 18.12.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Tuesday, July 29th. The company reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter in the previous year, the company posted $1.52 earnings per share. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. On average, analysts predict that United Therapeutics will post $8.55 earnings per share for the current fiscal year.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.